1. Home
  2. RVNC vs LSAK Comparison

RVNC vs LSAK Comparison

Compare RVNC & LSAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RVNC
  • LSAK
  • Stock Information
  • Founded
  • RVNC 1999
  • LSAK 1997
  • Country
  • RVNC United States
  • LSAK South Africa
  • Employees
  • RVNC N/A
  • LSAK N/A
  • Industry
  • RVNC Biotechnology: Pharmaceutical Preparations
  • LSAK Investment Bankers/Brokers/Service
  • Sector
  • RVNC Health Care
  • LSAK Finance
  • Exchange
  • RVNC Nasdaq
  • LSAK Nasdaq
  • Market Cap
  • RVNC 292.5M
  • LSAK N/A
  • IPO Year
  • RVNC 2014
  • LSAK N/A
  • Fundamental
  • Price
  • RVNC $3.58
  • LSAK $4.83
  • Analyst Decision
  • RVNC Buy
  • LSAK
  • Analyst Count
  • RVNC 9
  • LSAK 0
  • Target Price
  • RVNC $12.00
  • LSAK N/A
  • AVG Volume (30 Days)
  • RVNC 1.8M
  • LSAK 45.8K
  • Earning Date
  • RVNC 08-06-2024
  • LSAK 09-10-2024
  • Dividend Yield
  • RVNC N/A
  • LSAK N/A
  • EPS Growth
  • RVNC N/A
  • LSAK N/A
  • EPS
  • RVNC N/A
  • LSAK N/A
  • Revenue
  • RVNC $236,645,000.00
  • LSAK $551,325,000.00
  • Revenue This Year
  • RVNC $20.63
  • LSAK $9.63
  • Revenue Next Year
  • RVNC $34.80
  • LSAK $8.35
  • P/E Ratio
  • RVNC N/A
  • LSAK N/A
  • Revenue Growth
  • RVNC 54.59
  • LSAK 6.72
  • 52 Week Low
  • RVNC $2.30
  • LSAK $3.00
  • 52 Week High
  • RVNC $24.87
  • LSAK $5.33
  • Technical
  • Relative Strength Index (RSI)
  • RVNC 69.18
  • LSAK 56.10
  • Support Level
  • RVNC $2.40
  • LSAK $4.64
  • Resistance Level
  • RVNC $2.75
  • LSAK $4.84
  • Average True Range (ATR)
  • RVNC 0.23
  • LSAK 0.15
  • MACD
  • RVNC 0.13
  • LSAK -0.00
  • Stochastic Oscillator
  • RVNC 91.43
  • LSAK 72.09

About RVNC Revance Therapeutics Inc.

Revance Therapeutics Inc is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The company has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Its main products include DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics. The operating business segments are the Product and the Service Segment. The Products segment generates maximum revenue and is engaged in the research and development of aesthetic and therapeutic products.

Share on Social Networks: